Clinical Trials on Atrophic Scar in Belgium

Total 183 results

Eli Lilly and Company

Completed

A Study of LY2495655 in Older Participants Undergoing Elective Total Hip Replacement

Muscular Atrophy

Spain, United States, Belgium, Canada, Austria, Sweden, Japan, Finland, Denmark, Estonia, France
Biogen

Terminated

A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy (ENDEAR)

Spinal Muscular Atrophy

Korea, Republic of, United States, Spain, Canada, Germany, Australia, Japan, Sweden, Belgium, France, Italy, Turkey, United Kingdom
Biogen

Completed

A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies (SHINE)

Spinal Muscular Atrophy

United States, Spain, Germany, United Kingdom, Australia, Japan, Canada, Belgium, France, Hong Kong, Italy, Korea, Republic of, Sweden, Turkey
Maurizio Tonetti
The European Research Group on Periodontology (ERGOPerio)

Completed

Connective Tissue Graft Versus Mucograft Collagen Matrix for Coverage of Multiple Gingival Recession Defects

Gingival Recession

Italy, Belgium, Germany, Greece, Spain, Switzerland
Hoffmann-La Roche

Completed

A Study to Assess the Impact of Sarcopenia on the Outcomes of Colorectal Cancer Patients Treated With Chemotherapy Combined With Bevacizumab

Metastatic Colorectal Cancer

Belgium
University Hospital, Ghent
Groupe SEBBIN

Recruiting

Prospective Observational Study on SEBBIN Silicone Gel-filled Testicular Implants

Gender Dysphoria | Orchitis | Testicular Cancer | Prosthesis Durability | Testicular Torsion | Undescended Testes | Testicular Agenesis | Testicular Atrophy

Belgium
Biohaven Pharmaceuticals, Inc.

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy (RESILIENT)

Neuromuscular Diseases | Spinal Muscular Atrophy | SMA

United States, Netherlands, United Kingdom, Spain, Czechia, Belgium, Germany, Italy, Poland
Novartis Pharmaceuticals

Completed

Efficacy and Safety Study of QAW039 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis.

Atopic Dermatitis

South Africa, Belgium, Germany, Australia, Netherlands, Bulgaria, Austria, Romania
Novartis Pharmaceuticals
University of Pennsylvania

Recruiting

CAR-T Long Term Follow Up (LTFU) Study (PAVO)

Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program

United States, Japan, Australia, Germany, Spain, Belgium, Taiwan, Italy, Canada, Israel, Singapore, United Kingdom, Denmark, Finland, Norway, Austria, Netherlands, France
Biophytis

Completed

A Double-blind, Placebo Controlled, Randomized INTerventional Clinical Trial (SARA-INT) (SARA-INT)

Muscle Weakness | Sarcopenia | Gait Disorders in Old Age

United States, Belgium
Novartis Pharmaceuticals

Completed

A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core Study

Sarcopenia

Taiwan, United States, Belgium, Russian Federation, Korea, Republic of, Japan, France, Denmark, Australia, Czechia, Spain, Switzerland
BioMarin Pharmaceutical

Terminated

A Prospective Natural History Study of Progression of Subjects With Duchenne Muscular Dystrophy.

Duchenne Muscular Dystrophy

United States, Netherlands, Belgium, Germany, Argentina, Brazil, France, Italy, Sweden, Turkey
Italfarmaco
Fortrea

Recruiting

Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy (ULYSSES)

Duchenne Muscular Dystrophy

Belgium, Netherlands, Canada, Italy, France, Germany, United Kingdom
GlaxoSmithKline

Completed

Phase II Doubleblind Exploratory Study of GSK2402968 in Ambulant Subjects With Duchenne Muscular Dystrophy

Muscular Dystrophies

Germany, Belgium, Turkey, Netherlands, Spain, Israel, Australia, France, United Kingdom
Novartis Pharmaceuticals

Completed

Dose Range Finding Study of Bimagrumab in Sarcopenia

Sarcopenia

Belgium, United States, Australia, Germany, Spain, Taiwan, France, Korea, Republic of, Japan, Russian Federation, Denmark, Czechia, Switzerland
Wave Life Sciences Ltd.

Terminated

Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy (DYSTANCE 51)

Duchenne Muscular Dystrophy

United States, Belgium, United Kingdom, Czechia, Canada, France, Italy, Sweden
Janssen Research & Development, LLC

Recruiting

A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Geographic Atrophy

Netherlands, United States, Belgium, Italy, Germany, United Kingdom, Denmark, Spain, Czechia, Switzerland, Turkey, Canada, Hungary, Portugal, Poland, Australia, Sweden
Sarepta Therapeutics, Inc.

Active, not recruiting

Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Efficacy (Part B) in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment (MOMENTUM)

Duchenne Muscular Dystrophy

United States, Belgium, Spain, United Kingdom, Netherlands, Germany, Canada, Italy
Santhera Pharmaceuticals

Completed

Phase III Study of Idebenone in Duchenne Muscular Dystrophy (DMD) (DELOS)

Muscular Dystrophy, Duchenne | Ambulatory Care

United States, Spain, Austria, Belgium, France, Germany, Italy, Netherlands, Sweden, Switzerland
Astellas Pharma Global Development, Inc.

Active, not recruiting

Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy

Age-Related Macular Degeneration | Geographic Atrophy

United States, Italy, Latvia, France, Israel, Germany, Spain, Hungary, Brazil, Canada, Argentina, Colombia, Croatia, Australia, Austria, Belgium, Czechia
IVERIC bio, Inc.

Completed

A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)

Macular Degeneration | Geographic Atrophy

United States, Spain, France, Germany, Austria, Belgium, Israel, Poland, Canada, Italy, Estonia, Australia, United Kingdom, Hungary, Argentina, Brazil, Colombia, Croatia, Czechia, Latvia
Astellas Pharma Inc

Completed

Long-term Safety of Protopic in Atopic Eczema

Dermatitis, Atopic | Eczema, Atopic

France, Germany, United Kingdom, Spain, Belgium, Netherlands, Finland, Poland, Ireland, Hungary, Denmark, Latvia
Hoffmann-La Roche

Terminated

A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (CHROMA)

Geographic Atrophy

Canada, United States, Belgium, Peru, Argentina, Australia, Austria, Denmark, France, Germany, Hungary, Italy, Mexico, Netherlands, Poland, Slovakia, Spain, Switzerland, United Kingdom
Regeneron Pharmaceuticals
Sanofi

Completed

A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable

Atopic Dermatitis

Germany, Poland, Belgium, Netherlands, Russian Federation, Ireland, United Kingdom, Slovakia, Austria, Spain
Astellas Pharma Inc

Completed

Equivalence of the Response to Vaccination of Tacrolimus Ointment to a Steroid Ointment Regimen in Children With Atopic Dermatitis

Atopic Dermatitis

Australia, Belgium, Poland, Hungary, Portugal, Germany, Iceland, Malta
Hoffmann-La Roche

Terminated

A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (SPECTRI)

Geographic Atrophy

United States, United Kingdom, Netherlands, Germany, Belgium, Poland, Spain, Argentina, Australia, Hungary, Italy, Portugal, France, Turkey, Austria, Russian Federation, Mexico, Peru, Denmark, Slovakia, Sweden, Switzerland
Hoffmann-La Roche

Terminated

Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)

Geographic Atrophy

United States, United Kingdom, Germany, France, Turkey, Australia, Austria, Belgium, Canada, Denmark, Hungary, Italy, Poland, Slovakia, Spain, Switzerland, Portugal, Netherlands, Peru
PTC Therapeutics

Completed

Study of Ataluren for Previously Treated Participants With Nonsense Mutation Duchenne/Becker Muscular Dystrophy (nmDBMD) in Europe, Israel, Australia, and Canada

Duchenne Muscular Dystrophy | Becker Muscular Dystrophy | Dystrophinopathy

United Kingdom, Canada, Germany, Spain, Sweden, Italy, Australia, Belgium, France, Israel
LEO Pharma

Recruiting

A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy (ADHAND)

Atopic Dermatitis | Atopic Hand Eczema

United States, Canada, United Kingdom, Korea, Republic of, Netherlands, Belgium
Italfarmaco
Cromsource

Enrolling by invitation

Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study

Duchenne Muscular Dystrophy

Spain, United States, Canada, Belgium, France, Israel, Italy, Netherlands, Serbia, Germany, United Kingdom
Dyne Therapeutics

Recruiting

Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping (DELIVER)

Duchenne Muscular Dystrophy (DMD)

United States, Belgium, Canada, United Kingdom, Australia, Spain, Italy
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery

Muscle Wasting (Atrophy) After Hip Fracture Surgery

Colombia, Belgium, Hungary, Taiwan, Spain, Czechia, United States, France, Germany, Turkey, Japan, Russian Federation, United Kingdom, Argentina, Australia, Mexico, Chile, Switzerland, Austria
Sarepta Therapeutics, Inc.
Hoffmann-La Roche

Recruiting

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) (ENVISION)

Duchenne Muscular Dystrophy

Belgium, United States, Japan, Spain, Italy, United Kingdom
ReveraGen BioPharma, Inc.
University of Pittsburgh; Newcastle University; European Union; Cooperative International...

Completed

A Study to Assess the Efficacy and Safety of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy

United States, Belgium, Canada, United Kingdom, Spain, Netherlands, Sweden, Czechia, Australia, Greece, Israel
Santhera Pharmaceuticals

Terminated

Phase III Study With Idebenone in Patients With Duchenne Muscular Dystrophy (SIDEROS-E) (SIDEROS-E)

Duchenne Muscular Dystrophy

United States, Belgium, United Kingdom, Austria, France, Germany, Italy, Spain, Switzerland
LEO Pharma

Completed

Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis - ECZTRA 7 (ECZTRA 7)

Atopic Dermatitis

Belgium, France, Germany, Poland, United Kingdom, Czechia, Spain
Galderma R&D

Completed

Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

Moderate-to-Severe Atopic Dermatitis

United States, Belgium, Bulgaria, Estonia, France, Georgia, Germany, Hungary, Italy, Poland, Singapore
Italfarmaco
Syneos Health

Completed

Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

United States, Italy, Spain, Canada, Belgium, France, Germany, Israel, Netherlands, Serbia, United Kingdom
BioMarin Pharmaceutical

No longer available

Extension Study of Drisapersen in DMD Subjects

Duchenne Muscular Dystrophy

United States, Germany, United Kingdom, Japan, Netherlands, France, Spain, Korea, Republic of, Italy, Belgium, Taiwan, Argentina, Australia, Bulgaria, Czechia, Israel, Norway, Poland, Russian Federation, Turkey
Sarepta Therapeutics, Inc.
Hoffmann-La Roche

Active, not recruiting

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) (EMBARK)

Duchenne Muscular Dystrophy

United States, Japan, Taiwan, Belgium, Spain, Germany, Hong Kong, Italy, United Kingdom
Novartis Pharmaceuticals

Terminated

A Study to Assess the Safety and Efficacy of ZPL389 With TCS/TCI in Atopic Dermatitis Patients (ZESTExt)

Atopic Dermatitis

United Kingdom, Germany, Russian Federation, Taiwan, Belgium, Netherlands, Japan, Finland, Slovakia, United States, Iceland, Canada, Poland
Regeneron Pharmaceuticals
Sanofi

Terminated

Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis

United States, Korea, Republic of, Belgium, Czechia, Germany, Poland, Spain
LEO Pharma

Completed

Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3

Atopic Dermatitis

United States, Germany, Belgium, Canada, Spain, United Kingdom, Poland, Netherlands
Hoffmann-La Roche

Completed

Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

United States, Belgium, Canada, Australia, Japan, France, Netherlands, Spain, Argentina, Germany, Italy, United Kingdom, Sweden
Pfizer

Available

Abrocitinib Expanded Access Protocol in Adolescents and Adults With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

Taiwan, United States, Australia, Austria, Belgium, Canada, Greece, Mexico, Netherlands, Russian Federation, Spain, Switzerland
Astellas Pharma Inc

Completed

Treatment and Control of Atopic Dermatitis With 0.03% Tacrolimus Ointment

Dermatitis, Atopic

France, United Kingdom, Spain, Belgium, Portugal, Netherlands, Finland, Czech Republic, Germany, Hungary, Italy
FibroGen

Terminated

Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD) (LELANTOS-1)

Duchenne Muscular Dystrophy

United States, Belgium, Israel, Spain, Canada, Australia, Switzerland, United Kingdom, France, China, Netherlands, Italy, Austria, Czechia
FibroGen

Terminated

Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMD (LELANTOS-2)

Duchenne Muscular Dystrophy

United States, Spain, Canada, Australia, China, Italy, Belgium, France, Netherlands, Austria, United Kingdom
Astellas Pharma Inc

Completed

Treatment and Control of Atopic Dermatitis With 0.1% Tacrolimus Ointment

Dermatitis, Atopic

France, Germany, Spain, Belgium, Netherlands, Finland, Austria, United Kingdom, Italy, Czech Republic, Switzerland, Portugal, Denmark
Galderma R&D

Active, not recruiting

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

Moderate-to-Severe Atopic Dermatitis

United States, Australia, Austria, Belgium, Bulgaria, Canada, Czechia, Estonia, France, Georgia, Germany, Hungary, Italy, Korea, Republic of, Latvia, Lithuania, Netherlands, New Zealand, Poland, Singapore, Spain, United Kingdom

Clinical Trials on Atrophic Scar in Belgium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bulgaria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations